464 filings
8-K
ABBV
Abbvie Inc
26 Apr 24
AbbVie Reports First-Quarter 2024 Financial Results
7:43am
8-K
ABBV
Abbvie Inc
3 Apr 24
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
4:06pm
PX14A6G
Chevedden John
26 Mar 24
Letter to shareholders
2:31pm
ARS
2023 FY
ABBV
Abbvie Inc
18 Mar 24
Annual report to shareholders
4:27pm
DEFA14A
ABBV
Abbvie Inc
18 Mar 24
Additional proxy soliciting materials
4:17pm
8-K
j032bzo
26 Feb 24
Other Events
5:08pm
424B5
yxnv0xw
26 Feb 24
Prospectus supplement for primary offering
6:12am
FWP
xiyr6y wjl
22 Feb 24
Free writing prospectus
9:14pm
S-8
y3nkdc rra2q9w
22 Feb 24
Registration of securities for employees
5:50pm
424B5
2w56 386xiz7
21 Feb 24
Prospectus supplement for primary offering
8:39am
8-K
axq8 873pbdfoajj1
20 Feb 24
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
9:00am
8-K
3sm3 0muvv
12 Feb 24
AbbVie Completes Acquisition of ImmunoGen
7:49am
8-K
mr5y7unkn7e8a8vn6h
2 Feb 24
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
7:51am
8-K
3zycw4wz5x01cwxitrt
5 Jan 24
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
4:03pm
8-K
s6rwp lnowcs0x7ozc6
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
brs3hg7
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHEREĀ® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
25-NSE
2lm6 yv3c51zbpe27ypn
15 Nov 23
Exchange delisting
1:32pm